Immunic’s drug is currently being investigated in two Phase III trials in patients with relapsing multiple sclerosis.

The London Cancer Hub has been identified as a key district for ‘frontier innovation’ by London Mayor Sadiq Khan.

Among those consuming UPFs in high-income countries, intake varies significantly across age and socioeconomic status.

Neurocrine has commenced a Phase III registrational programme to assess NBI-1117568 as a treatment for schizophrenia in adult ...

Amylyx has dosed the first subject in the Phase III LUCIDITY trial of avexitide for treating post-bariatric hypoglycaemia ...